Clenpiq Shortage: What Providers and Prescribers Need to Know in 2026

Clenpiq Shortage: What Providers and Prescribers Need to Know in 2026

Bowel preparation compliance is one of the most important — and most overlooked — factors in colonoscopy quality. When patients can't fill their Clenpiq prescription, it creates downstream problems: rescheduled procedures, incomplete preps, and frustrated patients who may delay screening altogether.

This briefing covers the current state of Clenpiq availability, what's driving the access issues, and practical steps you can take to keep your patients on track.

Current Shortage Status

As of early 2026, Clenpiq is not listed on the FDA Drug Shortage Database. There is no formal nationwide shortage. However, providers across the country continue to report that patients are having difficulty filling Clenpiq prescriptions at retail pharmacies.

This is a distribution and stocking issue rather than a manufacturing shortage. The drug is being produced, but because it's a single-source brand product that many pharmacies don't routinely stock, patients frequently encounter "out of stock" responses — especially at chain pharmacies that rely on automated ordering systems.

Timeline and Background

Key dates and context for Clenpiq:

• 2012: Sodium picosulfate/magnesium oxide/citric acid first approved in the U.S. (Prepopik, powder formulation)
• 2017: Clenpiq (liquid formulation) approved by the FDA, manufactured by Ferring Pharmaceuticals
• 2021–2025: Periodic reports of pharmacy-level stock-outs, driven by single-source manufacturing and growing colonoscopy volumes
• 2026: No FDA-listed shortage, but sporadic availability issues persist. No generic approved; patents extend through 2034.

Prescribing Implications

The Clenpiq availability situation creates several practical considerations for prescribers:

Patient Compliance Risk

When a patient picks up their colonoscopy prep and the pharmacy doesn't have it, the default outcome is often a delayed colonoscopy. Studies consistently show that delays in colorectal cancer screening reduce detection rates and worsen outcomes. Anything that creates friction in the prep process is a barrier to screening compliance.

Prescription Timing

Consider writing the Clenpiq prescription well in advance of the scheduled procedure — ideally 1–2 weeks ahead. This gives the pharmacy time to order it and gives the patient time to find an alternative pharmacy if needed.

Alternative Prep Readiness

Having a backup plan in place before the patient encounters a stock-out saves time and prevents last-minute scrambling. Many practices now include a note in their colonoscopy scheduling workflow: "If Clenpiq is unavailable, contact our office for an alternative prescription."

Availability Picture

Understanding the distribution dynamics helps explain why patients struggle:

• Single manufacturer: Ferring Pharmaceuticals is the sole manufacturer of Clenpiq. No other company produces this specific liquid formulation.
• No generic competition: The FDA has not approved a generic version of Clenpiq. Patent protection extends through 2034.
• Demand-driven stocking: Most retail pharmacies order Clenpiq only when a prescription comes in, rather than maintaining standing inventory. Wholesaler fulfillment typically takes 1–3 business days.
• Volume pressure: The USPSTF recommendation to begin colorectal screening at age 45 (expanded from 50) has increased colonoscopy volumes, putting additional demand pressure on all bowel prep products.

Cost and Access Considerations

Cost can be a secondary barrier, particularly for uninsured or underinsured patients:

• Cash price: $193–$253 per prep (2 bottles)
• With commercial insurance: Typically $20–$75 copay
• Manufacturer savings card: Eligible commercially insured patients may pay as low as $50. Cash-paying patients save up to $40. Available at clenpiq.com or through the HCP portal.
• Discount cards: GoodRx and SingleCare coupons can bring the cash price to approximately $181–$200
• Patient assistance: Ferring Pharmaceuticals offers patient assistance programs. Contact 1-888-FERRING (1-888-337-7464) or visit ferringusa.com

For a patient-facing cost guide to share: How to Save Money on Clenpiq in 2026.

Tools and Resources for Providers

Real-Time Stock Checking

Medfinder for Providers allows you to check real-time pharmacy stock for Clenpiq and other medications in your patient's area. This can be integrated into your colonoscopy scheduling workflow to proactively identify availability issues before they become patient problems.

Alternative Bowel Preps

When Clenpiq isn't available, consider these evidence-based alternatives:

• Suprep (Sodium Sulfate/Potassium Sulfate/Magnesium Sulfate) — Low-volume liquid, widely available. Generic options exist.
• Sutab (Sodium Sulfate/Magnesium Sulfate/Potassium Chloride) — Tablet form, excellent patient compliance.
• Suflave (Sodium Sulfate/Magnesium Sulfate/Potassium Chloride Powder) — Flavor-free, low-volume. Approved 2023.
• GoLYTELY (PEG-3350/Electrolytes) — High-volume but very affordable ($10–$30 generic). Universally available.

Each has different contraindication profiles, particularly regarding renal function. Clenpiq and Suprep both contain magnesium and require caution in patients with CrCl <30 mL/min. GoLYTELY may be preferred in patients with significant renal impairment.

Patient Education Materials

These patient-facing articles can be shared with patients who are having trouble finding Clenpiq:

• How to Find Clenpiq in Stock Near You
• Alternatives to Clenpiq If You Can't Fill Your Prescription
• Clenpiq Shortage Update: What Patients Need to Know in 2026

Looking Ahead

With Clenpiq patents extending through 2034, generic competition is unlikely in the near term. The practical reality for prescribers is that Clenpiq will remain a single-source product with periodic access challenges for the foreseeable future.

To mitigate this:

• Build Clenpiq availability checks into your pre-procedure workflow
• Maintain familiarity with 2–3 alternative preps and their relative contraindications
• Educate staff to proactively contact patients if pharmacy issues arise
• Use Medfinder for Providers as a real-time tool for stock verification

Final Thoughts

The Clenpiq availability situation in 2026 is manageable but requires proactive planning. As the sole prescriber in the colonoscopy prep equation, you have significant influence over whether a stock-out becomes a delayed screening or a seamless switch to an alternative. Building availability checks and backup plans into your workflow protects your patients and your procedure schedule.

Additional resources for your practice:

• How to Help Your Patients Find Clenpiq in Stock: A Provider's Guide
• How to Help Patients Save Money on Clenpiq: A Provider's Guide